

# Investigating Antimicrobial Resistance in Salmonella Meningitis: A Nigerian Perspective

**Aisha Jibril, Omolara Afolabi, Abdoulaye Maïga, Josephine Yaro,  
Amira Issa, Jacques Kaboré**

*1Department of Microbiology, School of Public Health, University of Niamey, Niamey,  
Niger*

## Abstract

*Salmonella* meningitis prognosis is poor and the choice of adequate antibiotic therapy is difficult in developing countries where laboratory testing is not accessible. This study aimed to evaluate, the antibiotic susceptibility pattern of *salmonella* isolated from CSF in meningitis suspected cases and to identify the best drug option. From 2011 to 2015, 6630 CSF collected were sent at CERMES, during laboratory-based surveillance. All turbid and freshly collected CSF from under 5 years patients were subjected to standard bacteriological method for isolation and characterization of meningitis etiologies. A total of 11/6630 *Salmonella* strains were isolated during this study. This accounted for 0. 2% of the overall CSF analyzed during the 5 years of study. Most of the patients (72.7%) were less than 2 years old. The average age of children was 2.63 years with an extreme of 1 month to 14 years and the sex ratio M/F was 0.83. The antimicrobial susceptibility was performed in vitro, to all the 11 *salmonella* isolated. The result revealed that 9/11(81.8%) strains were susceptible to ceftriaxone, Amikacin, and Cefoxitin. All the isolates (100%) were sensitive to Imipenem, Nalidixic acid, and Ciprofloxacin. Two strains of *salmonella* (18.2%) belonged to extended-spectrum beta lactamase (ESBL) producing group. The maximum resistance was observed against Ampicillin (100%), Amoxicillin/clavulanic acid (72.7%) and Gentamicin (27.3%). The Ampicillin MIC value showed 100% resistance to all the strains tested. This study confirmed that ceftriaxone may be used to treat *Salmonella* meningitis. The isolation of ESBL *salmonella* strain may be an alarm indicating the worldwide spray of multi-resistant bacterium. However, the limitation in the use of cephalosporin may prevent this increasing resistance.

## Introduction

*Salmonella* is a widespread food born disease encountered frequently in developing country with sanitation problem. Meningitis due to *salmonella* is relatively uncommon but it is of importance because of high mortality rate (Though the disease is known to be the fourth cause of meningitis in children, after *Neisseria meningitidis* (Nm), *Streptococcus pneumoniae* (*S.pn*), and *Haemophilus influenzae type b*

Christensen & Frederiksen 1988). (*H.i b*) (OwusuOfori & Scheld 2003). Salmonellosis is a public health problem highly associated with septicemia in children and adult (Mahalakshmi 2013; Kanchanapongkul 1995) The infection may

spread from intestine to blood stream causing bacteremia (Altun *et al.* 2014). Pregnant woman may also transmitted the infection to his baby as carrier (Olivares Lopez *et al.* 1981). The disease prognosis is poor and the choice of adequate antibiotic therapy is difficult where laboratory testing is not accessible (Fuller *et al.* 2003; Khemiri *et al.* 1984). Antimicrobial agents previously used seem to be not efficient. Though, there is limited data from Africa (LONGE *et al.* 1984). *Salmonella* antimicrobial resistance has been reported from both developed and particularly in developing countries where the choice of antimicrobial treatment may be a problem (Kanchanapongkul 1995). In fact, some isolates were now resistant to

ampicillin and not all were sensitive to Gentamicin and Chloramphenicol (Fuller *et al.* 2003). This antimicrobial resistance has been a serious public health problem (S. & G. 1951; Mahalakshmi 2013). New treatment with ceftriaxone and other third generation cephalosporin were recommended (Anon 2015). The combination of quinolone and ceftriaxone were suggested as an alternative solution (Price *et al.* 2000; OwusuOfori & Scheld 2003). *Salmonella* meningitis is rare or often neglected in Niger. It's then difficult to estimate the fatality rate due to *salmonella* meningitis. However, the disease mostly occurs in neonates and young infants (Ali *et al.* 2017).

So far, no recommended treatment against *Salmonella* meningitis was available in Niger. The ministry of health was recommended the use of Ceftriaxone 2g daily for a minimum of five days in the treatment of meningococcal meningitis (OMS, 2015). Thus Patients may be treated with common used antibiotics against meningococcal meningitis.

#### *Objectives:*

This work aimed to evaluate in vitro, the antibiotic susceptibility pattern of *salmonella* isolated from CSF in meningitis suspected cases and to identify the best drug option.

## **Material and methods**

### *Samples collection*

This retrospective study was conducted at Center for medical and Health research (CERMES), the National Reference Laboratory for meningitis in Niger from January 2011 to December 2015. Cerebrospinal spinal fluids (CSF) were collected nationwide from suspected cases and sent to CERMES for analysis. All freshly collected CSF were subject to culture by standard bacteriological method for isolation and characterization of bacterial meningitis etiologies (culture, Gram, latex, antimicrobial sensibility). Socio-demographic information and history of the infection were also collected and analyzed in the study.

### *Salmonella isolation and identification*

CSF were cultured on Blood Agar Plate which is a trypticase soy agar (TSA) plate containing 5% sheep blood; and on chocolate agar plate supplemented with hemin (X factor) and nicotinamide-adenine-dinucleotide (NAD; V factor). Plates were then incubated in candle jar for 18-24 hours at 35-37°C with 5% CO<sub>2</sub>. All media were previously tested for growth and sterility with reference strains as part of quality control. All Bacteria that appeared Gram Negative rod shaped bacilli after Gram staining, were considered as suspect of *salmonella* and purified on nutrient agar after 18 to 24 hours period of incubation at 37°C.

Suspected *salmonella* colonies were confirmed by biochemical reactions (motility, indole production, lysine decarboxylase, carbohydrate fermentation) using 20E API kit (Biomérieux, Marcy l'étoile, France) and serotyped by slide agglutination with *Salmonella* antigen antisera (Williamson & Murti 1990; GEORGES *et al.* 1AD; Berk & McCabe 1980). Then, agglutination test was carried out using a panel of *salmonella* antisera according to Kauffmann and White scheme.

### *Antibacterial susceptibility*

Antimicrobial susceptibility test was performed by Kirby Bauer disk diffusion methods in respect to European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2016). Identified pure culture of *Salmonella* was inoculated on Muller-Hinton agar plate (Liofilchem, Italy) with a depth of 4mm. Bio-Rad antibiotics discs were used to screen for susceptibility according to EUCAST 2016. *Escherichia coli* American Type Culture Collection (ATCC25922) were used as quality control strains and for Minimal Inhibitory Concentration (MIC) determination.

All *Salmonella* isolates were tested for resistance to 9 antimicrobial agents: Ampicillin (AM, 10 µg), Amikacin (AKN, 30µg), Amoxicillin/clavulanic acid (AMC, 10 µg), Ciprofloxacin (CIP, 5 µg), ceftriaxone (CRO, 30µg), Cefoxitin (CTX, 30µg) Gentamicin

(GEN,10µg), Imipenem (IPM,10µg), and Nalidixic acid (AN,30µg), according to recommendations of Clinical and Laboratory Standards Institute (Anon n.d.).

In case of resistance the MIC was performed by using E-test (Bio-Mérieux). The inhibition zones were measured by Venire Caliper to categorize the isolate as susceptible, intermediate, resistant or non-susceptible (Baud & Aujard 2013; Watson 1957). All the isolates were conserved in Trypticase Soy Broth + 15% glycerol at -80°C for further research work.


**Results**

*Salmonella* meningitis is uncommon in Niger. A total of 11/6630 *Salmonella* strains were isolated during 2011-2016 meningitis based surveillance. The disease is rare and accounted for 0. 2% of the overall CSF analyzed at CERMES during the 5 years of study. Most of the patients were children (72.7%) less than 2 years old.

The average age of children was 2.63 years with an extreme of 1 month to 14 years and the sex ratio M/F was 0.83. of the eleven *salmonella* species detected, we found 7 (63.7%) *Salmonella typhi*, 2 (16.7%) *Salmonella* spp, 1(8.3%) *Salmonella paratyphi* A and 1(8.3%) *Salmonella paratyphi* B. The antimicrobial susceptibility was performed to all the 11 *salmonella* isolated and the results were shown in Fig. 1. In current study, the antimicrobial susceptibility testing in vitro, revealed that 9/11 (81.8%) strains were susceptible to ceftriaxone, ciprofloxacin and Cefoxitin. All the isolates (100%) were sensitive to Imipenem and Nalidixic acid.

Two strains of *salmonella* (18.2%) belonged to Extended-Spectrum Beta Lactamase (ESBL) producing group as shown in Fig. 1. The maximum resistance was observed against Ampicillin (100%), followed by Amoxicillin/clavulanic acid (72.7%), Amikacin

(27.3%) and Gentamicin (27.3%). The Ampicillin MIC value (0.0µg/ml) also shown 100% resistant to all the 11 strains tested (Fig. 2).



**Fig. 1.** Antibiotics resistance profile of *Salmonella* isolates collected from CSF.



**Fig. 2.** Broaded spectrum Beta lactamase *Salmonella paratyphi* (ESBL).



**Fig. 3.** Ampicillin Minimum Inhibition Concentration (MIC).

## Discussion

The treatment of *salmonella* meningitis is presently difficult since the disease is often neglected (Workman *et al.* 1999; Price *et al.* 2000). *Salmonella* meningitis is poorly or not reported from Niger. The bacterium may be neglected or not notified as cause of meningitis due to the absence of modern laboratory facilities in many areas (ARSLAN Ahmed, 2012). Another reason is that, in case of any symptom such as headache, fever, relative to meningitis, medical and health professionals evoke *Neisseria*, *streptococcus* and *Heamophilus* bacteria. The disease occurs particularly in the dry season from December to June.

Young children were mostly affected in endemic area as revealed by other studies worldwide (Doctor *et al.* 2001; LOW *et al.* 1984). The reason may be due to mother carrier, hygiene and alimentation problem A. Ali *et al.* (2017). Salmonellosis infection is almost always by fecooral route (Kumar *et al.* 2014).

Most serogroupes isolated in this study, were known to cause typhoid fever (typhi and paratyphi). This may probably be explained by sanitation problem. In this study all the *salmonella* isolated were sensitive to Imipenem and ciprofloxacin used to treat salmonellosis in this part of the world. This finding is in concordance with the result of Sangaré *et al.*, (2007) in Burkina Faso, and Olafemi *et al.*, (2000) in Nigeria, but different from Helms *et al.*, (2002) result in Ghana. About 9/11 strains (81.8%) were sensitive to ceftriaxone the most used and recommended antibiotic for meningitis treatment in Niger (WHO, 2015). This antibiotic with good diffusion may be efficient against *salmonella* (Owusu-Ofori & Scheld 2003; Fuller *et al.* 2003). This work showed that early treatment with ceftriaxone together or not with Ciprofloxacin could lead to good cure rate (Thiombiano *et al.* 2007; Coldiron *et al.* 2017). However, the previously used antibiotics Ampicillin, and Gentamicin were inefficient (Owusu-Ofori & Scheld 2003). Ampicillin has been primarily used

as drug of choice in the treatment of meningitis in Niger, though some rural health centers still used it in case of emergency. According to our result, all *salmonella* strains tested were resistant to Ampicillin (100%) and (27.3%) were resistant to Gentamicin as stated early by Elisabeth Price (2000) and Scheld (2003) in Ghana. The result of MIC showed that Ampicillin was resistant and may be inefficient in the treatment of *Salmonella* meningitis in this part of the meningitis belt as told by Owusu-Ofori and Scheld 2003 from Ghana. In our study, 2(0.2%) *salmonella* isolates were found to produce an extended-spectrum beta lactamase (ESBL).

This may probably indicate the emergence of new multi-resistant *salmonella* strain to third generation cephalosporin such as ceftriaxone and Amoxicillin/clavulanic acid. According to our finding, these ESBL producers were 100% sensitive to carbapenems. Similar data about Imipenem were presented by Alipourfard *et al.* (2010) in Bangladesh.

## Conclusion

This study conducted for the first time in Niger revealed and confirmed that ceftriaxone may be suggested in the treatment of *Salmonella* meningitis either alone or in combination with Ciprofloxacin. This study also showed that quinolones were very efficient whereas ampicillin was completely inefficient in the treatment of *Salmonella* meningitis. Thus, the isolation of ESBL *salmonella* strain may be an alarm indicating the worldwide spray of multi-resistant bacterium. However, the limitation in the use of cephalosporin may prevent this increasing resistance.

## References

- Ali A, Zanguina J.** 2017. First report of *Salmonella* meningitis during 2011-2015 meningitis surveillance in Niger **5(6)**, pp.1-6.
- Altun HU.** 2014. Antimicrobial susceptibilities of clinical *Acinetobacter baumannii* isolates with

different genotypes. *Jundishapur Journal of Microbiology* **7(12)**, pp. 2012-2015.

**Anon.** 2015. CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-Tenth Edition. CLSI document M2-A10. Wayne, PA: Clinical and Laboratory Standards Institute pp. 27-33.

**Anon.** 2015. Contribution de l'OMS à la gestion de l'épidémie de méningite au Niger.

**Baud O, Aujard Y.** 2013. Neonatal bacterial meningitis. *Handbook of Clinical Neurology* **112**, pp.1109-1113.

**Berk SL, McCabe WR.** 1980. Meningitis Caused by Gram-Negative Bacilli. *Ann Intern Med* **93(2)**.

**Christensen AC, Frederiksen W.** 1988. Etiology of bacterial meningitis. *Ugeskrift for læger* **150**, pp.655-657.

**Coldiron ME.** 2017. Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial. *Trials* **18(1)**, p.294.

**Doctor BA.** 2001. Clinical outcomes of neonatal meningitis in very-low birth-weight infants. *Clin Pediatr (Phila)*, **40(9)**, pp.473-480.

**Fuller DG.** 2003. Antibiotic treatment for bacterial meningitis in children in developing countries. *Annals of tropical paediatrics* **23(4)**, pp.233-53.

**GEORGES AJ, 1AD.** Aspects bactériologiques et cliniques des infections à *Salmonella typhi* en République Centrafricaine: bilan d'une étude de 3 années à Bangui (French). *Bacteriological and clinical aspects of infections due to salmonella typhi in Central African Republic (English)* **77(2)**, pp.164-174.

**Kanchanapongkul J.** 1995. *Salmonella*: a rare cause of meningitis in an adult. *The Southeast Asian journal of tropical medicine and public health* **26(1)**, pp.195-197.

**Khemiri F, Boujaafar N, Aloui M.** 1984. [Antibiotic resistance of *Salmonella* during 1982 and 1983]. *Antibioresistance des Salmonella au cours des années 1982 et 1983*, **61**, pp.107-121.

**Kumar JD.** 2014. A rare case of *Salmonella typhi* meningitis in a two-month-old infant: A case report. *Pediatric Infectious Disease* **6(3)**, pp.97-98.

**LONGE AC, OMENE JA, OKOLO AA.** 1984. Neonatal Meningitis in Nigerian Infants. *Acta P?? diatrica* **73(4)**, pp.477-481.

**LOW LCK.** 1984. *Salmonella* meningitis in infancy. *Journal of Paediatrics and Child Health* **20(3)**, pp.225-228.

**Mahalakshmi R.** 2013. *Salmonella paratyphi B* meningitis in an infant. *Australasian Medical Journal*, 2009 **(181)**, pp.350-353.

**Olivares Lopez F.** 1981. [Meningitis caused by *Salmonella*]. *Boletin Medico del Hospital Infantil de Mexico* **38**, pp.103-110.

**Owusu-Ofori A, Scheld WM.** 2003. Treatment of *Salmonella* meningitis: Two case reports and a review of the literature. *International Journal of Infectious Diseases* **7(1)**, pp.53-60.

**Price EH, Workman MR.** 2000. Antibiotics for *Salmonella* meningitis in children. *The Journal of antimicrobial chemotherapy* **46(5)**, pp.653-5.

**SL, GB.** 1951. A case of *salmonella* (paratyphoid B) meningitis in a premature infant with recovery. *Harefuah* **41(6)**, pp.96-98.

**Thiombiano R.** 2007. M éningites dues à Salmonella au CHU de Ouaga- dougou Burkina Faso (2000-2004) **(1)**, pp.53-56.

**Williamson M, Murti PK.** 1990. A bacteriological study of purulent meningitis in children. Indian journal of pathology & microbiology **33(2)**, pp.157-160.

**Workman MR, Price EH, Bullock P.** 1999. Salmonella meningitis and multiple cerebral abscesses in an infant. International Journal of Antimicrobial Agents **13(2)**, pp.131-132.